Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00223249
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : April 4, 2016
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center

September 15, 2005
September 22, 2005
April 4, 2016
November 2002
August 2004   (Final data collection date for primary outcome measure)
Number of Standard Drinks [ Time Frame: Weekly ]
Not Provided
Complete list of historical versions of study NCT00223249 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence.
The abuse of alcohol is especially common in people with bipolar disorder. However, very little is known about the pharmacotherapy of people with both bipolar disorder and alcohol abuse/dependence. The purpose of this study is to determine if alcohol use and cravings are decreased with quetiapine add-on therapy compared to placebo and to determine if quetiapine add-on therapy is associated with greater improvement in mood, impulsivity, functioning and decreased alcohol use than placebo.
Experimental: After obtaining informed consent, 100 patients with bipolar I, or II disorders and alcohol abuse/dependence confirmed by a structured clinical interview (SCID) will be enrolled. from referral sources in the community we have developed over the past 3 years. A medical history and physical examination, including an eye exam with an ophthalmoscope, will also be performed at baseline to rule out serious medical illnesses and cataracts. Baseline labs including a liver panel and CBC will be obtained. Women of child-bearing potential will be given a urine pregnancy test. Baseline measures of psychiatric symptoms will be assessed with the HRSD, YMRS, and Barratt Impulsiveness Scale. Alcohol cravings will be assessed with the Obsessive Compulsive Drinking Scale (OCDS). Alcohol use including number of drinks/2 weeks, days used in the past two weeks, and days of heavy use will be obtained as will a urine drug/alcohol screen. Alcohol use and cravings will also be recorded throughout the study. Side-effects will be assessed with a general side effects scale, the Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), and Barnes Akathesia Rating Scale (BARS). GGT levels will also be repeated at weeks 6 and 12. The subjects will be randomized and receive quetiapine or identical appearing placebo add-on therapy in a double-blind fashion for 12 weeks. Subjects will return every two weeks for reevaluation with the above outcome measures and for upward titration of study drug. All subjects will be given the option of receiving open-label quetiapine for an additional 4 weeks (with continuing assessment of mood and alcohol use/cravings every 2 weeks) at the end of the study or discontinuing medication.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Bipolar Disorder
  • Alcohol Abuse/Dependence
Drug: Quetiapine
  • Active Comparator: Quetiapine
    Intervention: Drug: Quetiapine
  • Placebo Comparator: Placebo
    Inactive ingredient matching the active medication in appearance
    Intervention: Drug: Quetiapine
Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2008 May;69(5):701-5.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
August 2004
August 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Bipolar I or II
  • Ages 18-70

Exclusion Criteria:

  • Life threatening medical condition causing participation in the study hazardous
  • Alcohol abuse within the past 2 weeks
  • History of cataracts or likely cataracts on baseline eye exam
  • History of hepatic cirrhosis or AST or ALT more than three times normal limit
  • Current active suicidal or homicidal ideation
  • History of allergic reaction, poor response or intolerable side effects to quetiapine
  • Antipsychotic use within 7 days of beginning quetiapine therapy
  • Mental retardation, dementia or other severe cognitive impairment
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
Not Provided
Principal Investigator: E. Sherwood Brown, Ph.D., M.D. The UT Southwestern Medical Center at Dallas
University of Texas Southwestern Medical Center
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP